Warburg effect was first described as a mechanism by which the tumor cells rely on glycolysis to power proliferation and biosynthesis (Hsu and Sabatini, [@B4]). The transcription factor, hypoxia-inducible factor--1α (HIF-1α), and the serine/threonine protein kinase, mammalian target of rapamycin (mTOR), are major drivers of this metabolic switch (Lu et al., [@B6]; Sun et al., [@B14]). In recent years a number of reports have shown that immune cells such as monocytes, macrophages, dendritic cell, and T cells utilize a similar mechanism during activation (Palsson-McDermott and O\'Neill, [@B10]). It is known that activated monocytes/macrophages switch their core metabolism from oxidative phosphorylation to glycolysis (Rodríguez-Prados et al., [@B11]; Liu et al., [@B5]). This process is similar to the Warburg effect in tumor cells because the activated immune cells need a readily available source of energy for phagocytosis, oxidative burst, and biosynthetic precursors to divide and produce cytokines.

The mechanism of such metabolic switching remains unclear but a recent article by Cheng et al. sheds light on this crucial process (Cheng et al., [@B1]). They studied the mechanism by which monocytes acquire trained immunity (Figure [1](#F1){ref-type="fig"}). This is a process by which monocytes on initial stimulation undergo epigenetic programing by histone modification, leading to stronger gene transcription upon restimulation (Netea et al., [@B9]). Using a model of β-glucan exposure of macrophages and subsequent LPS stimulation they show that the macrophages undergo epigenetic upregulation of genes expressing mTOR and glycolysis, that are targets of the transcription factor HIF-1α. The β-glucan trained monocytes showed elevated aerobic glycolysis, reduced basal respiration rate and increased glucose consumption and lactate production. This was associated with a decrease in oxygen consumption and reduced mitochondrial capacity, consistent with a metabolic shift from oxidative phosphorylation to glycolysis. This process occurs through the activation of Akt-mTOR-HIF-1α pathway. Blocking of the mTOR-HIF-1α pathway by chemical inhibitors abrogated the trained immunity and indirect inhibition of mTOR by AICAR (an activator of adenosine monophosphate-activated protein kinase, AMPK) had similar effects. Significantly, myeloid specific HIF1α deficient mice were not protected in a model of β-glucan induced tolerance against *S. aureus* sepsis, indicating that this pathway is important for septic responses.

![**Glycolysis as metabolic basis for trained immunity**. In resting monocytes the metabolism is predominated by oxidative phosphorylation, providing a majority of adenosine triphosphate (ATP) as the energy source. Activated monocytes during induction of trained immunity undergo a metabolic shift toward glycolysis, the Warburg effect, mediated by Akt-mTOR- HIF-1α.](fphys-06-00070-g0001){#F1}

This important study by Cheng et al. adds to a growing number of recent studies that have demonstrated that glycolytic flux and metabolic intermediates are drivers of immune responses. For example, macrophages exposed to LPS show a shift from oxidative phosphorylation to glycolysis (Rodríguez-Prados et al., [@B11]); and succinate, an intermediate in the TCA cycle, induced Interleukin 1beta (IL-1β) production (Tannahill et al., [@B15]). In addition, Glucose transporter 1 (Glut1) mediated increase in glycolysis drives a proinflammatory phenotype in macrophages (Freemerman et al., [@B2]). The realization that oncogenesis and immune responses have a common underlying mechanism of metabolic switching indicates that this fundamental biological process can be a potential drug target for many diseases. An important clinical application of the concept of metabolic switching is in the identification of therapeutic targets in sepsis.

Sepsis, a systemic inflammatory reaction to infection, is the leading cause of death in the world. The incidence of sepsis worldwide is 18 million every year with 30% mortality. The economic impact of sepsis is substantial with costs of up to \$50,000/patient and \$17 billion annually in United States alone (Slade et al., [@B12]; Moss, [@B8]). While in most cases we can control the infection with antibiotics, we lack therapies to minimize the hyperactive inflammatory response and downstream target injury (Lyle et al., [@B7]). Higher levels of lactate (product of glycolysis) and its slower rate of clearance during resuscitation predicts worse outcome in sepsis (Garcia-Alvarez et al., [@B3]). It is commonly thought that the lactate elevation is secondary to poor perfusion or microcirculatory disturbances, but it appears from recent studies that the lactate is more than just a marker of circulatory abnormalities and likely indicates a fundamental shift in metabolism to a more proinflammatory glycolysis. In line with this concept, a recent study has shown that pyruvate kinase M2- HIF-1α mediated Warburg effect drives mortality in sepsis (Yang et al., [@B16]). Our data on macrophages indicates that preservation of mitochondrial function under inflammatory conditions leads to attenuated cytokine responses (Srivastava et al., [@B13]). The mechanism by which metabolic switching regulates inflammatory processes is a novel and promising area of research. By targeting the upstream events in the inflammatory cascade we may get effective therapies for sepsis as well as for other inflammatory disorders.
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